Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...